The role of syndecan-1 during endometrial carcinoma progression

Solmaz, Özgen Arslan

doi:10.4103/jcrt.jcrt_364_17

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Syndecan-1 families are anchored on the endothelial cell membrane and can bind to glycosaminoglycan chains, which form Proteoglycans, through specific binding sites [ 21 ]. Heparin sulfate (HS) is the most common glycosaminoglycan chains [ 22 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…Phosphatidylinositol proteoglycan (Glypican) and Syndecan-1 families anchored on the endothelial cell membrane belong to the core proteins of GCX [ 27 ]. Syndecan-1 can be divided into extracellular segment, intracellular segment, and transmembrane domain, and its extracellular segment can be bind to GAG through specific binding sites [ 21 ]. Chondroitin sulfate, HS, and hyaluronic acid (HA) are the most common GAG [ 22 , 23 ], and of which HS accounts for about 50% ~ 90%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ropivacaine with intraspinal administration alleviates preeclampsia-induced kidney injury via glycocalyx /alpha 7 nicotinic acetylcholine receptor pathway

Sun

Tian

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Preeclampsia is characterized by hypertension and proteinuria, which is associated with kidney injury. Glycocalyx (GCX) degradation mediated endothelial injury can result in proteinuria and kidney damage. alpha 7 nicotinic acetylcholine receptor (α7nAChR) connects nervous and immune systems to respond to stress or injury. We aimed to explore the protective effect and mechanism of intraspinal analgesia on maternal kidney injury in preeclampsia. Endotoxin-induced preeclampsia rats treated with ropivacaine via intraspinal administration. Renal histopathological examination was performed, cell apoptosis in the kidney, the levels of Glycocalyx markers of Syndecan-1 and heparin sulfate (HS) in maternal serum, Syndecan-1 along with α7nAChR in the kidney were measured. Our results showed that kidney injury was obviously in preeclampsia rats with proteinuria, endothelial damage, higher apoptosis rate, increasing levels of Syndecan-1 and HS in serum, upregulated Syndecan-1 expression but downregulated α7nAChR expression in kidney. Preeclampsia rats treated with intraspinal injected ropivacaine attenuated preeclampsia-induced kidney injury as Syndecan-1 and HS were decreased in serum, Syndecan-1 expression was suppressed as well as α7nAChR was activated in the kidney. Our results suggested that Ropivacaine administered through the spinal canal may protect preeclampsia-induced renal injury by decreasing GCX and α7nAChR activation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ropivacaine with intraspinal administration alleviates preeclampsia-induced kidney injury via glycocalyx /alpha 7 nicotinic acetylcholine receptor pathway

Sun

Tian

et al. 2022

Bioengineered

View full text Add to dashboard Cite

show abstract

Targeting syndecan-1: new opportunities in cancer therapy

Yang

Chen

Ying

et al. 2022

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

Syndecan-1 (SDC1, CD138) is one of the heparan sulfate proteoglycans and is essential for maintaining normal cell morphology, interacting with extracellular and intracellular protein repertoire as well as mediating signaling transduction upon environmental stimuli. The critical role of SDC1 in promoting tumorigenesis and metastasis has been increasingly recognized in various cancer types, implying a promising potential of utilizing SDC1 as a novel target for cancer therapy. This review summarizes the current knowledge on SDC1 structure and functions, including its role in tumor biology. We also discuss the highlights and limitations of current SDC1-targeted therapies as well as the obstacles in developing new therapeutic methods, offering our perspective on the future directions to target SDC1 for cancer treatment.

show abstract

Syndecan-1 and E-Cadherin Expression in Canine Cutaneous Squamous Cell Carcinoma

Files,

Cardoso,

Prada

et al. 2024

Veterinary Sciences

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (CSCC) in dogs is a locally invasive tumor that typically occurs in areas of poorly pigmented skin due to sun exposure. Identifying new biomarkers, such as syndecan-1 (CD138) and E-cadherin, is fundamental for tumor diagnosis and prognosis. Dysregulation of syndecan-1, expressed in epithelial tissue, fibroblasts, and plasma cells, is associated with poor prognosis in several types of cancer. Similarly, E-cadherin, which plays a crucial role in cell adhesion and epithelial functionality, is also linked to adverse outcomes. This study evaluated the expression of syndecan-1 and E-cadherin in 47 cases of canine cutaneous squamous cell carcinoma. The results showed that the intensity of syndecan-1 decreased with increasing tumor aggressiveness, and its presence in the stroma was significantly associated with tumor grade. E-cadherin also demonstrated a decrease in intensity with increasing malignancy. However, the association between syndecan-1 and E-cadherin was not statistically significant. E-cadherin reduction and stromal syndecan-1 positivity seem to be associated with tumor aggressiveness in canine cutaneous squamous cell carcinoma. Further studies are needed to explore their roles in tumor progression.

show abstract

The role of syndecan-1 during endometrial carcinoma progression

Cited by 3 publications

References 3 publications

Ropivacaine with intraspinal administration alleviates preeclampsia-induced kidney injury via glycocalyx /alpha 7 nicotinic acetylcholine receptor pathway

Ropivacaine with intraspinal administration alleviates preeclampsia-induced kidney injury via glycocalyx /alpha 7 nicotinic acetylcholine receptor pathway

Targeting syndecan-1: new opportunities in cancer therapy

Syndecan-1 and E-Cadherin Expression in Canine Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About